Holen Sie sich die Stockscreener-App
83.16
0.44%
0.39
Schlusskurs vom Vortag:
$82.77
Offen:
$82.77
24-Stunden-Volumen:
389.11K
Relative Volume:
0.48
Marktkapitalisierung:
$3.89B
Einnahmen:
$1.35B
Nettoeinkommen (Verlust:
$163.34M
KGV:
25.38
EPS:
3.2763
Netto-Cashflow:
$189.17M
1W Leistung:
+3.72%
1M Leistung:
-0.96%
6M Leistung:
+10.65%
1J Leistung:
+6.96%
1-Tages-Spanne:
$82.52
$83.68
1-Wochen-Bereich:
$79.06
$83.68
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
83.16 | 3.87B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
127.09 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.88 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.81 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.86 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Is Haemonetics (NYSE:HAE) Using Too Much Debt? - 富途牛牛
Haemonetics Corporation (HAE) Stock Analysis: Insights into a Promising Medical Device Leader with a 9.85% Upside - DirectorsTalk Interviews
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well - simplywall.st
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Allspring Global Investments Holdings LLC Boosts Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Fort Washington Investment Advisors Inc. OH Has $34.43 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Boston Trust Walden Corp - MarketBeat
Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth? - Smartkarma
Harbor Capital Advisors Inc. Purchases 14,226 Shares of Haemonetics Corporation $HAE - MarketBeat
Do You Believe in the Long-Term Growth Potential of Haemonetics Corporation (HAE)? - Yahoo Finance
Aug PostEarnings: What risks investors should watch in Haemonetics Corporation stockJuly 2025 Action & AI Forecast for Swing Trade Picks - moha.gov.vn
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
Haemonetics Is Maintained at Outperform by Mizuho - 富途牛牛
Will Haemonetics Corporation stock profit from AI boomMarket Performance Report & Precise Buy Zone Identification - Улправда
Assenagon Asset Management S.A. Invests $8.56 Million in Haemonetics Corporation $HAE - MarketBeat
Is it apt to retain Haemonetics stock in your portfolio now? - MSN
Haemonetics (FRA:HAZ) EV-to-OCF : 15.32 (As of Dec. 19, 2025) - GuruFocus
Here's Why Haemonetics (HAE) is a Strong Growth Stock - Yahoo Finance
Why Haemonetics Corporation stock is considered a top pickJuly 2025 Levels & Risk Controlled Swing Alerts - DonanımHaber
Why Haemonetics Corporation (HAZ) stock could rally stronglyWeekly Risk Summary & AI Powered Buy/Sell Recommendations - DonanımHaber
What risks investors should watch in Haemonetics Corporation stockBull Run & Safe Entry Momentum Tips - Улправда
MACD Signal: Is Haemonetics Corporation stock in correction or buying zoneDollar Strength & Daily Growth Stock Investment Tips - Улправда
Haemonetics (HAE) Valuation Check After Needham Downgrade on Rising Vascular Closure Competition - simplywall.st
Haemonetics Expands Medical Solutions Across Global Healthcare - Kalkine Media
Haemonetics (NYSE:HAE) Price Target Raised to $90.00 - MarketBeat
HAE Receives Rating Update from Mizuho with Raised Price Target - GuruFocus
Haemonetics price target raised to $90 from $75 at Mizuho - TipRanks
Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors? - Yahoo Finance
Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation (HAE) in Q3 - Yahoo Finance
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 - 富途牛牛
Haemonetics (HAE) Downgraded by Needham Amid Competition Concerns - GuruFocus
Haemonetics downgraded to Hold from Buy at Needham - TipRanks
HAE: Baird Raises Price Target to $99, Rating Remains Outperform - GuruFocus
Why Haemonetics Shares Are Facing Turbulence - TipRanks
Why Haemonetics (HAE) Shares Are Trading Lower Today - Yahoo Finance
Here's Why Haemonetics (HAE) is a Strong Momentum Stock - Yahoo Finance
Haemonetics price target raised to $99 from $87 at Baird - TipRanks
Needham downgrades Haemonetics stock to Hold on vascular closure device competition concerns - Investing.com
Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target - marketscreener.com
HAE Downgraded to Hold by Needham in Recent Ratings Update | HAE Stock News - GuruFocus
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $99 - 富途牛牛
ETFs investiert in Haemonetics Corporation-AktienTradingView - TradingView - Alle Märkte im Blick
Haemonetics (NYSE:HAE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Haemonetics (NYSE:HAE) Price Target Raised to $74.00 at JPMorgan Chase & Co. - MarketBeat
JP Morgan Maintains Haemonetics (HAE) Neutral Recommendation - MSN
Haemonetics (HAE) Receives Updated Neutral Rating with Raised Pr - GuruFocus
Haemonetics price target raised to $74 from $62 at JPMorgan - TipRanks
Is it Apt to Retain Haemonetics Stock in Your Portfolio Now? - Yahoo Finance
Citi downgrades Haemonetics (HAE) to a Hold - The Globe and Mail
Why Haemonetics (HAE) Stock Is Down Today - Finviz
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):